MolecuLight
- Company typePrivate
- Founded2012
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
MolecuLight firmographics
Firmographics- Name
- MolecuLight
- Legal name
- MolecuLight Inc.
- Website
- https://moleculight.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
MolecuLight industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
- akta.pro secondary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where MolecuLight is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
MolecuLight business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: MolecuLight generates revenue primarily from the sale of its MolecuLight i:X and DX fluorescence imaging devices, which are FDA Class II cleared, CE marked, and Health Canada approved handheld wound imaging systems. Device sales are made directly in the US and Canada and through authorized distributors globally.
- Accessories and Consumables: MolecuLight sells accessories including DarkDrape (for creating clinical darkness), WoundStickers (for wound measurement), and i:X Sterile Surgical Sleeve Convenience Kit (one-time use, disposable items). These consumables generate recurring revenue as procedures are performed.
- Reimbursement via CPT Codes: The MolecuLight procedure qualifies for reimbursement in the United States through two CPT Category III codes for 'fluorescence imaging for bacterial presence, location, and load'. Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) facility payment is available through APC assignment. This provides a reimbursement pathway supporting healthcare provider adoption.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Medical device with pricing provided via quote; no public pricing listed |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels8 records
MolecuLight product offering
Product offeringCore offering
MolecuLight develops and manufactures FDA-cleared Class II handheld fluorescence imaging devices (MolecuLight i:X and MolecuLight DX) that detect elevated bacterial burden in wounds in real time at the point of care using safe violet excitation light. The flagship MolecuLight DX additionally combines digital wound measurement and thermal imaging in a single device for wound care clinicians, hospitals, and outpatient wound care clinics. The company also sells associated consumable accessories such as DarkDrape, WoundStickers, and sterile surgical sleeves.
Product overview
MolecuLight offers a portfolio of point-of-care fluorescence imaging devices for wound care. The core products are the MolecuLight i:X and MolecuLight DX — handheld FDA-cleared Class II medical devices that provide real-time detection of elevated bacterial burden (>104 CFU/g) in wounds through fluorescence imaging, along with digital wound measurement capabilities. The DX model represents the enhanced platform with additional thermal imaging features. The product suite includes accessories such as the i:X Sterile Surgical Sleeve Convenience Kit for use in operating rooms, DarkDrape for creating imaging darkness, and WoundStickers for wound measurement. The company operates under an ISO 13485:2016 Quality Management System and has achieved FDA clearance, CE marking, and Health Canada approval.
Differentiator
Problem solved
Functional benefit
Brands
- MolecuLight i:X: First FDA-cleared handheld fluorescence imaging device for real-time detection of bacterial burden in wounds at point-of-care
- MolecuLight DX
Products and services
- MolecuLight DX All-in-one handheld point-of-care wound imaging device that combines fluorescence imaging for real-time detection of elevated bacterial burden (>104 CFU/g) in wounds, digital wound measurement (>95% accuracy), and thermal imaging (±0.5°C accuracy). FDA Class II cleared and the only wound care device also qualified by the FDA as a Medical Device Development Tool (MDDT). For wound care clinicians, hospitals, long-term care facilities, and burn centers.
- MolecuLight i:X Handheld FDA-cleared Class II fluorescence imaging device for point-of-care detection of elevated bacterial burden (>104 CFU/g) in wounds. Allows clinicians to view, digitally record, and measure wounds while detecting bacterial presence through fluorescence using safe violet excitation light, with red fluorescence indicating general bacteria and cyan fluorescence specifically indicating Pseudomonas aeruginosa.
- i:X Sterile Surgical Sleeve Convenience Kit FDA-cleared kit enabling wound care practitioners to safely use the MolecuLight i:X in sterile fields. Includes sterile sleeve, non-sterile adhesive adapter, sterile paper ruler, and instructions for use.
- DarkDrape Wound care accessory that creates the darkness needed to capture MolecuLight fluorescence images when room lights cannot be turned off during wound imaging procedures.
- WoundStickers Disposable stickers placed on either side of wounds for digital wound measurement using the MolecuLight i:X and DX imaging devices.
Quantifiable outcome
- 79% greater reduction in wound area by 12 weeks when harmful bacteria detected by MolecuLight are removed
- +10 more outcomes
Companies that use MolecuLight
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles3 records
MolecuLight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature6 records
MolecuLight partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and significant.
- University Health Network (UHN)coreUniversity Health Network (UHN), Canada's largest research hospital network, exclusively licensed U.S. Patent No. 10,438,356 to MolecuLight. This patent covers the fluorescence imaging technology used for real-time visualization of bacteria in wounds. MolecuLight founder Dr. Ralph DaCosta is a scientist at Princess Margaret Cancer Centre, part of UHN.
- Net HealthcoreNet Health integrated MolecuLight's wound imaging devices with its Tissue Analytics platform, enabling improved bacterial detection and data analytics for wound care providers. The integration enhances interoperability with Net Health's WoundExpert and other EHR systems, supporting automated documentation and comprehensive wound assessment.
- OraclecoreMolecuLightDX became available on Oracle Healthcare Marketplace, enabling direct connection with Oracle's EHR system. The device integrates bacterial detection, digital wound measurements, and thermal imaging through Oracle's healthcare platform to improve wound care workflows.
- Perceptive SolutionssignificantMolecuLight Corp. entered into a partnership with Perceptive Solutions to integrate its bacterial imaging technology with the WoundZoom platform, extending the reach of MolecuLight's wound imaging capabilities through Perceptive Solutions' wound measurement technology.
- Premier, Inc.corePremier, Inc. awarded MolecuLight a group purchasing agreement for its i:X and DX point-of-care wound imaging devices in the Skin Integrity category. Premier's alliance includes more than 4,400 U.S. hospitals and 225,000 other healthcare providers who can access special pricing and terms pre-negotiated by Premier. MolecuLight also received Premier's Technology Breakthrough designation.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
MolecuLight competitors and assessment
Company assessmentDirect peers
- Kent Imaging: Kent Imaging is a Canadian medical imaging company developing near-infrared fluorescence imaging devices (including SnapshotGLO) for wound and tissue perfusion assessment. It is the most direct competitor to MolecuLight, named as a respondent in MolecuLight's ITC patent infringement complaint.
- Spectral AI: Spectral AI (formerly SpectralMD) develops DeepView, an AI-driven multispectral imaging system that assesses wound healing potential by analyzing tissue viability. It targets the same wound care clinical market as MolecuLight with a complementary optical imaging approach.
- HyperMed Imaging: HyperMed Imaging produces hyperspectral imaging devices (HyperView) used to assess tissue oxygenation and perfusion in wounds and burn injuries. It competes with MolecuLight in point-of-care optical wound assessment, particularly in burn and vascular wound applications.
- Adiuvo Diagnostics: Adiuvo Diagnostics is an India-based developer of fluorescence-based wound imaging technology (subject of MolecuLight's ITC complaint and a contested Indian patent). It is a direct competitor in the multi-spectral fluorescence pathogen detection space.
Others
- Net Health: Net Health is a wound care EHR and analytics platform (including Tissue Analytics and WoundExpert) that MolecuLight integrates with. It is a channel/integration partner rather than a direct competitor, providing wound care documentation workflows that incorporate MolecuLight's imaging data.
- Perceptive Solutions: Perceptive Solutions develops the WoundZoom digital wound measurement platform, integrated with MolecuLight's bacterial imaging. It is a complementary technology partner in the wound care documentation ecosystem rather than a direct imaging competitor.
Broad incumbents
- Smith+Nephew: Smith+Nephew is a large global medical device company with a substantial Advanced Wound Management portfolio (including PICO, ACTICOAT, and ALLEVYN). As a broad incumbent, it overlaps with MolecuLight in serving wound care clinicians and hospitals, though its focus is on dressings and NPWT rather than point-of-care diagnostic imaging.
- ConvaTec: ConvaTec is a major wound and ostomy care company offering dressings, skin barriers, and related consumables through its Advanced Wound Care franchise. It addresses the same wound care customer base as MolecuLight but focuses on therapeutic products rather than diagnostic imaging devices.
- Mölnlycke Health Care: Mölnlycke Health Care is a Swedish medical device company specializing in wound care (Mepilex, Mepitel, Avance NPWT) and surgical solutions. It is a broad incumbent in wound care selling to the same hospital and clinician customers as MolecuLight, but without a point-of-care imaging offering.
- Coloplast: Coloplast is a Danish medical device company with a strong Wound Care business (Biatain, Comfeel) alongside its Ostomy and Continence Care franchises. It serves the same chronic wound patient population and clinician customers as MolecuLight but is focused on therapeutic consumables rather than diagnostic imaging technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
MolecuLight social profiles
Digital presenceMolecuLight compliance and trust
Trust signalCompliance6 records
MolecuLight financial estimates
Financial estimateRevenue estimate
Valuation estimate
MolecuLight leadership team
Management profileNumber of profiles
Profiles11 records
MolecuLight subsidiaries and ownership
Company hierarchySubsidiaries2 records
MolecuLight funding detail
Funding detailFunding overview
Funding rounds8 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MolecuLight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MolecuLight
What does MolecuLight do?
MolecuLight develops and manufactures FDA-cleared Class II handheld fluorescence imaging devices (MolecuLight i:X and MolecuLight DX) that detect elevated bacterial burden in wounds in real time at the point of care using safe violet excitation light. The flagship MolecuLight DX additionally combines digital wound measurement and thermal imaging in a single device for wound care clinicians, hospitals, and outpatient wound care clinics. The company also sells associated consumable accessories such as DarkDrape, WoundStickers, and sterile surgical sleeves.
Is MolecuLight a public or private company?
MolecuLight is a private company. It is classified as venture growth investor backed and is currently operating.
When was MolecuLight founded?
MolecuLight was founded in 2012. It employs 1 to 10 people.
Where is MolecuLight based?
MolecuLight is headquartered in Toronto, Canada, in the North America region.
How does MolecuLight make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are accessories and Consumables and reimbursement via CPT Codes.
Who are MolecuLight's main competitors?
Direct peers on record are Kent Imaging, Spectral AI, HyperMed Imaging and Adiuvo Diagnostics. Others are Net Health and Perceptive Solutions. Broad incumbents are Smith+Nephew, ConvaTec, Mölnlycke Health Care and Coloplast.
Does MolecuLight have an API?
No public API is recorded for MolecuLight.
What industry is MolecuLight in?
MolecuLight's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334510 and its SIC code is 3845.